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We examined the hypothesis that recovery from uncomplicated malaria in patients carrying drug-resistant
Plasmodium falciparum is a measure of acquired functional immunity and may therefore be associated with
humoral responses to candidate vaccine antigens. Gambian children with malaria were treated with chloro-
quine in 28-day trials, and recovery was defined primarily as the absence of severe clinical malaria at any time
and absence of parasitemia with fever after 3 days. Plasma samples from these children were assayed by
enzyme-linked immunosorbent assay for immunoglobulin G (IgG) to recombinant merozoite antigens: apical
membrane antigen 1 (AMA-1) and the 19-kDa C-terminal region of merozoite surface protein 1 (MSP-119),
including antigenic variants of MSP-119 with double and triple substitutions. Antigen-specific IgG was more
frequent in children who recovered, particularly that for MSP-119 (age-adjusted odds ratios: 0.32 [95%
confidence interval, 0.05, 1.87; P  0.168] for AMA-1, 0.19 [0.03, 1.11; P  0.019] for recombinant MSP-119,
0.24 [0.04, 1.31; P  0.032] for the recombinant MSP-119 double variant, and 0.18 [0.03, 0.97; P  0.013] for
the triple variant). IgG titers to MSP-119 and to the triple variant were higher in plasma samples taken 7 days
after chloroquine treatment from children who carried resistant parasites but recovered and remained parasite
free. Moreover, in children who were parasitemic on day 14 or day 28, there was an age-independent relation-
ship between parasite density and IgG to both MSP-119 and the triple variant (coefficients of 0.550 and
0.590 and P values of 0.002 and 0.001, respectively). The results validate the use of this approach to identify
antigens that are associated with protection from malaria.
The development of a malaria vaccine is increasingly impor-
tant in the face of the growing worldwide threat of the disease
(29, 35). Since vaccine-induced immune responses are often
short-lived, many vaccine strategies aim to elicit protective
immune responses that may be boosted by subsequent expo-
sure to natural infection. Such responses are commonly iden-
tified by longitudinal cohort studies. Residents of an area
where malaria is endemic are sampled for a particular immune
response and then monitored for parasite infection or disease
over the next few months to determine susceptibility (18, 27,
32, 33). In such studies, functional immunity may be defined as
the result of a lower probability of developing clinical malaria,
high parasite levels, or infection. Disadvantages of this method
include the following. (i) Exposure to infection is an important
confounder but is difficult to measure. (ii) The time between
baseline sampling and endpoint detection allows immune re-
sponses to wax or wane, possibly depending on subclinical or
microscopically subpatent infection rates. (iii) The burden of
such studies is high in terms of both participant inconvenience
and research costs. Alternative ways of identifying individuals
with functional protective immunity could greatly improve our
ability to evaluate parasite antigens as vaccine candidates.
Three studies have investigated the relationship between
antibody and therapeutic success in malaria patients. In Sene-
gal (34) and Thailand (24), antibody responses to the repetitive
circumsporozoite protein antigen and ring erythrocyte surface
antigen, respectively, were shown to be more prevalent in pa-
tients who recovered than in patients with treatment failure.
The third study, in Gabon (23), showed no association between
outcome and antibody responses to several recombinant mer-
ozoite surface protein 1 (MSP-1) polypeptides, including the
conserved 19-kDa C-terminal MSP-119, although there was an
association with antibody to K1 and MAD 20 allelic families
of the MSP-1 block 2 region. Although acquired immune re-
sponses may be more important in drug-resistant infections,
parasite genotypes were not determined. Mutations in the Pfcrt
and Pfmdr1 genes are associated with resistance to chloroquine
(CQ), but the Pfcrt-76Thr variant appears most strongly asso-
ciated with CQ resistance in all populations examined so far (9,
36, 38). In addition, in Malawi, the prevalence of the Pfcrt-
76Thr variant decreased in the parasite population after CQ
treatment was discontinued, while that of the Pfmdr1-86Tyr
variant remained unchanged (28).
In much of West Africa, where CQ monotherapy has been
the first-line therapy for uncomplicated malaria, treatment fail-
ure rates tend to be lower among older children (10), and a
similar tendency is seen even when resistance to the treatment
drug is very low (13); these observations may reflect a contri-
bution from acquired immunity. Djimde´ and colleagues (11)
therefore proposed that treatment response is a phenotype for
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identifying host responses that provide protective immunity
against malaria. Elimination of parasites by the immune system
requires effectors that target blood-stage asexual parasites, and
B cells and antibodies are known to play a key role in protec-
tive immunity against these stages, as shown by passive immu-
nization studies with mice and humans (8, 21, 25).
Antibodies may act in a variety of ways, for example by
preventing merozoite invasion of erythrocytes, by attacking
infected erythrocytes, probably in conjunction with monocytes,
or by preventing cytoadhesion of infected erythrocytes (19).
Molecules important to all three of these processes have been
identified as candidate vaccines, but those involved in mero-
zoite invasion have been the most studied. Several merozoite
surface molecules are well characterized (e.g., MSP-1 to -9,
erythrocyte binding antigen-175, and apical merozoite antigen
1 [AMA-1]). There is evidence to implicate antibodies from
malaria-immune donors in the inhibition of parasite invasion
of erythrocytes, especially antibodies specific for MSP-119 (2,
20) and the ectodomain of AMA-1 (recently reviewed in ref-
erence 32). Some cohort studies have shown that the presence
of antibody to MSP-1 is associated with lower rates of clinical
malaria in the following high-transmission season (1, 15), al-
though other studies (e.g., reference 12) found no such asso-
ciation. Similarly, evidence for a protective role for AMA-1 in
vivo had been elusive until a recent cohort study showed an
association of antibodies to the ectodomain, with protection
from clinical malaria in Kenyans (32). This variation in results
may reflect limitations in the cohort method as outlined above
or the need for a more precise definition of the antibody. For
example, the fine specificity of MSP-119 antibodies, together
with their prevalence and titer level, may better predict pro-
tection (30, 31, 39). Some MSP-119-specific antibodies actually
block the binding of protective antibodies, highlighting the
need to measure functional antibody (20).
We hypothesized that following drug treatment, antibodies
to these merozoite surface molecules play a role in the elimi-
nation of Plasmodium falciparum in areas where drug resis-
tance is highly prevalent. In 2000 and 2001, pediatric treatment
trials for uncomplicated malaria conducted in The Gambia
included CQ comparison arms (14, 37). We have used plasma
and data from these trials and examined whether antibodies to
AMA-1 and MSP-119 are associated with clinical recovery and
elimination of parasites. Three forms of MSP-119 were used as
antigens: a naturally occurring sequence and two variants that
have been modified to reduce the binding of blocking antibod-
ies (20).
MATERIALS AND METHODS
Study population and samples. During the 2000 and 2001 malaria high-trans-
mission seasons, children of 1 to 10 years of age attending Farafenni MCH clinic
with symptoms of uncomplicated malaria were screened, and eligible children
were invited to participate in a clinical trial of antimalarial drug treatment. Two
hundred fifty-three children (130 in 2000 and 123 in 2001) were treated with CQ
and followed for 28 days (details in references 14 and 37). Finger pick plasma
samples donated at enrollment (day 0) were available from 58 patients in 2000,
all of whom were enrolled in the first 7 weeks of the 9-week trial; there were no
differences in screening characteristics and outcomes between those with and
those without plasma samples (results not shown). In addition, children found to
have gametocytes on day 7 during these trials were asked to give a venous blood
sample for transmission experiments (14). Day 7 plasma samples were therefore
available for a subset of 47 patients. Plasma samples were stored at 20°C, and
whole blood samples, also collected on day 0 and day 7, were stored dried on
filter paper for DNA extraction and genotyping. Clinical and parasitological data
were collected for 28 days after treatment. Parasites were quantified by micro-
scopic examination of Giemsa-stained thick blood smears (16). Children lost to
follow-up were excluded, since their response to treatment could not be classi-
fied, leaving 46 day 0 and 44 day 7 plasma samples, 12 of which were from the
same children, for analysis.
To compare antibody responses in the malaria cases with those in healthy
children, control samples were selected from those taken in a cross-sectional
community-based survey of children in the study area shortly before the start of
the 2000 high-transmission season and frequency matched by age to the malaria
cases in 1-year age bands. These studies were approved by the Joint Gambian
Government/MRC Ethics Committee.
Parasite genotyping. Extracted DNA was genotyped for Pfcrt-76Thr/Lys by
PCR-restriction fragment length polymorphism using methods described previ-
ously (9, 36).
Enzyme-linked immunosorbent assay (ELISA). The ectodomain of AMA-1
FVO strain expressed in Pichia pastoris was donated by Alan Thomas, BPRC,
The Netherlands (22). It was purified by affinity chromatography with nickel
resin and ammonium sulfate precipitation and found to be pure by gel electro-
phoresis. Recombinant MSP-119 (wild-type [WT] Wellcome sequence, accession
number P04933) was prepared by standard techniques as a glutathione S-trans-
ferase (GST) fusion protein. Two modified MSP-119 antigens were also prepared
as GST fusion proteins: a triple variant that carries three amino acid substitutions
(Glu27 to Tyr, Leu31 to Arg, and Glu43 to Leu) and a double variant with two
substitutions (Cys12 to Ile and Cys28 to Trp, which thus lacks a disulfide bond).
(Amino acid residues are numbered from Asn1 at the N terminus of MSP-119.)
Both variants lack one or more epitopes for blocking antibodies (39). GST served
as a control for the recombinant MSP-119 antigens.
Plasma samples were relabeled so that laboratory staff would be unaware of
treatment outcome. ELISAs were conducted as described in references 6 and 32.
Antigens were coated onto 96-well polystyrene plates at 1 g/ml (Immulon 4;
Thermo Lab Systems, United Kingdom), and plasma samples were assayed in
duplicate at a 1:1,000 dilution. Bound antibodies were detected with a horserad-
ish peroxidase-conjugated rabbit anti-human immunoglobulin G (IgG) (Dako,
Glostrup, Denmark) and developed with o-phenylenediamine dihydrochloride
substrate (Sigma, United Kingdom).
A positive standard (PS) high-titer adult serum sample was included on every
plate, and mean optical densities (ODs) were normalized between assays using
the following formula: (OD of sample)  (overall mean OD of PS)/(day mean
OD of PS). ODs for the MSP-119 recombinants were corrected for the binding
of IgG to GST alone. Negative responses for all ELISAs were defined as those
below the mean OD  3 SD of a single batch of 40 individual sera from adults
who had never previously visited an area of malaria endemicity. Background
mean and SD values for AMA-1 were 0.235 and 0.144, giving a cutoff value of
0.668. For MSP-119 antigens, the background mean and SD values for GST, WT,
triple variant, and double variant were 0.126 and 0.060, 0.088 and 0.034, 0.073
and 0.029, and 0.090 and 0.033, respectively, giving cutoff values of 0.104, 0.107,
and 0.085. Plasma samples positive for the total IgG conjugate were also ana-
lyzed with an IgG subclass ELISA by use of sheep anti-human horseradish
peroxidase conjugates (The Binding Site, Birmingham, United Kingdom); cutoff
values for AMA-1, MSP-119 WT, and the triple variant were 0.058, 0.021, and
0.014, respectively, for IgG1 and 0.107, 0.016, and 0.018, respectively, for IgG3.
To quantify IgG to MSP-119, WT, and the triple variant more precisely, assays
were repeated with serial dilutions and antibody concentrations were estimated
by comparison to standard curves generated using purified polyclonal human
IgG (The Binding Site, United Kingdom) (7).
Statistical methods. Statistical analysis was done using STATA version 8
(Stata Corporation, College Station, Texas) and logXact version 6 (Cytel Soft-
ware Corporation). The primary analysis was a determination of the influence of
specific antibody in plasma taken at enrollment (day 0) on the risk of clinical
failure by day 28. Clinical failure was defined as presence of (i) severe malaria on
days 1 to 28, (ii) parasitemia and fever (37.5°C) on days 3 to 28, and (iii)
parasitemia on day 3 25% of that on day 0 (40). In a secondary analysis, we
investigated the association of antibody responses on day 7 with late parasito-
logical failure, defined as parasitemia on day 14 or day 28, and with the density
of parasitemia on these days. Children who had neither clinical nor parasitolog-
ical failure as defined above were considered to have cleared their parasites.
CQ-resistant infections were defined as those where the Pfcrt-76Thr allele was
detected in the day 0 sample. Characteristics thought to be potential confounders
of the relationship between immunological variables and treatment outcome
were age and the presence of drug-resistant parasite genotypes. Odds ratios for
treatment failure were calculated with mid-P values, which are less conservative
than exact tests, and exact confidence intervals. The two-sample Wilcoxon rank-
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sum (Mann-Whitney) test was used to compare antibody titers or concentrations
between groups. Correlation between parasitemia level, including zero values,
and IgG concentration was examined using Spearman’s rank correlation test, and
the magnitude of the effect on parasitemia was further assessed by calculating the
arithmetic mean parasitemia level by category of IgG response.
RESULTS
Study group characteristics. Plasma samples and parasite
genotyping data were available from 78 patients: 46 sampled
on day 0, of whom 12 were sampled again on day 7, and an
additional 32 patients sampled on day 7. These groups of
patients were similar in age, anemia level (as estimated by
packed cell volume), ethnicity, and asexual parasite density
(Table 1), but carriage of parasites with the Pfcrt-76Thr geno-
type was higher among patients sampled only on day 7: 30/32
individuals (95%) compared to 31/46 (67%) among those sam-
pled on day 7. This increase was likely due to the higher
proportion of gametocytemic donors in the day 7 group, as
there is a correlation between gametocytemia and drug resis-
tance (17, 26). Clinical failures occurred soon after treatment,
13/16 (81%) before day 14, and all parasitological failures were
detected on day 14 (29/45) or on day 28 (16/45), with a mean
detection time point of 18.9 days.
Association of pretreatment IgG with clinical outcome.
Prevalence of antibody for each of the antigens was higher in
children who did not experience clinical failure than in those
that did (Table 2); for example, 6 of the 37 children with
detectable pretreatment antibody that recognized WT MSP-119
failed treatment, while 5 of the 9 children without such anti-
body failed treatment. Similar results were obtained for the
other proteins: children with antibody to these merozoite an-
tigens were between three and six times as likely to recover
without relapse. Odds ratios adjusted for age were similar to
unadjusted odds ratios, indicating that age was not a significant
confounder in this analysis (Table 2). Antibody titers, esti-
mated as median OD values in responders, were not signifi-
cantly associated with clinical outcome (results not shown).
Two-thirds (31/46 [67%]) of patients were carrying the Pfcrt-
76Thr allele, which is strongly associated with failure of CQ
treatment. Although the association between the presence of
antibody and treatment outcome appeared to be stronger in
the group that had drug-resistant parasite genotypes on day 0,
this observation was difficult to test formally because of the
small sample size.
There was considerable homogeneity in responder status for
the different antigens; only 8 out of the 46 children (17%) were
discrepant in their response to AMA-1 and WT MSP-119, and
none of these experienced clinical failure. There were discrep-
ancies in responses to the variant MSP-119 antigens; two sam-
ples were negative for the triple variant alone and one sample
was negative for both the triple and double variants while
containing antibodies reacting with the wild-type antigen.
Comparison of antibody response in malaria patients and in
healthy children. To explore the dynamics of these responses
in relation to malarial disease, we compared the prevalence
and titers of IgG to AMA-1 and WT MSP-119 found in the
malaria patients on day 0 to those in clinically normal children
sampled before the start of the high-transmission season. As
TABLE 1. Study population
Characteristic
Value for indicated characteristic for group
sampled on day:
0 (n  46) 7 (n  32)
Mean age in yr (SD) 4.54 (2.19) 4.74 (2.38)
Mean packed cell volume (%)
(SD)
31.72 (5.75) 29.84 (4.59)
Ethnic type (no. [%] within
sample group)
Mandinka 17 (37) 17 (53)
Wolof 14 (30) 9 (28)
Fula 11 (24) 3 (9)
Other 4 (9) 3 (9)
Geometric mean no. of asexual
P. falciparum parasites/l
on day 0 (range)
2,673 (1,500–270,000) 2,124 (500–278,000)
No. within sample group
positive for presence of
Pfcrt-76Thr allele at day 0
31 (67%) 30 (94%)
TABLE 2. Treatment outcome and the presence of IgG to AMA-1 or MSP-119 antigens on day 0
a
Status for indicated
antibody on day 0
No. of patients with
clinical failure/total (%)
Odds ratio (95% CI; P value)
Unadjusted Adjusted for age
AMA-1
Negative 5/11 (45) 1 1
Positive 6/35 (17) 0.27 (0.05, 1.46; 0.076) 0.32 (0.05, 1.87; 0.168)
WT MSP-119
Negative 5/9 (56) 1 1
Positive 6/37 (16) 0.18 (0.03, 1.06; 0.017) 0.19 (0.03, 1.11; 0.019)
Triple-variant MSP-119
Negative 6/12 (50) 1 1
Positive 5/34 (15) 0.19 (0.03, 0.98; 0.013) 0.18 (0.03, 0.97; 0.013)
Double-variant MSP-119
Negative 6/11 (55) 1 1
Positive 5/35 (14) 0.23 (0.04, 1.25; 0.028) 0.24 (0.04, 1.31; 0.032)
a Specific IgG was detected by ELISA in plasma from children on day 0 and antibody and therapeutic responses classified as indicated in Materials and Methods.
Exact 95% confidence intervals (95% CI) and mid-P values are given for the crude odds ratios and after adjustment for age.
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would be expected in this region of malaria endemicity,
almost half (21/46) of the clinically normal children had
detectable parasitemia, but the mean parasite density was
over 100-fold lower than that in the malaria patients. Preva-
lence of IgG to these antigens was similar between the groups,
but titers varied: anti-MSP-119 titers were significantly higher
in the clinical cases (median OD of 0.487 and 25th and 75th
quartiles [IQR] of 0.241 and 1.411 versus OD of 2.609 and IQR
of 1.745 and 3.352; P  0.0001), while AMA-1 titers appeared
lower (median OD of 3.367 and IQR of 1.931 and 3.826 versus
OD of 2.075 and IQR of 1.322 and 3.571), but not significantly
so.
Association of posttreatment IgG with parasitological out-
come. In contrast to the patients who provided plasma on day
0, most patients who donated plasma on day 7 were infected
with Pfcrt-76Thr parasites (Table 1). We selected day 7 donors
carrying Pfcrt-76Thr parasites to compare IgG responses and
parasitological outcomes. There were 31 donors in total, of
whom 8 cleared their parasites. The frequency of responders
was high—over 87% for all antigens—and there was no signif-
icant association between IgG responder status and parasito-
logical failure (results not shown). However, antibody titers,
estimated as median OD values in positive samples, to the
MSP-119 antigens were associated with parasitological clear-
ance at marginal significance (P values were 0.083 for the wild
type and 0.097 for the double variant [Table 3]). To examine
this relationship more precisely, specific IgG concentrations in
positive day 7 plasma samples were calculated. The data obtained
supported the conclusion that IgG concentrations were higher in
children with controlled parasitemia (Table 3).
These results prompted us to examine the relationship be-
tween level of parasitemia, defined as the highest value found
on day 14 or 28, and specific IgG to the antigens. Categorizing
responders for each antigen into approximately equal groups
of low, medium, and high responders revealed a trend toward
descending parasitemia: for WT MSP-119, the corresponding
mean values were 21,419, 15,783, and 638 asexual P. falcipa-
rum/l, and for the triple variant, mean parasitemia values
were 27,625, 12,567, and 622 asexual P. falciparum/l. Spear-
man’s correlation coefficients were 0.550 and 0.590, with P
values of 0.002 and 0.001, for WT MSP-119 and the triple
variant, respectively. The concentration of these antibodies
was not associated with age; P values were 0.497 and 0.548 for
WT MSP-119 and the triple variant, respectively. (In contrast,
AMA-1-specific antibody levels, estimated from OD values of
positive responders, showed a marginally significant associa-
tion with age [P  0.086].)
Further analysis of posttreatment IgG to wild-type and tri-
ple-variant MSP-119. The presence of IgG1 and IgG3 sub-
classes in the specific response was determined by ELISA for
all positive plasma samples from day 7, including those from
patients with clinical failure. IgG1 was detected in over 90% of
IgG-positive samples, and IgG1 titers correlated well with
those found using the non-class-specific conjugate. IgG3 spe-
cific for AMA-1 was present in only 1/33 samples, but IgG3
specific for MSP-119 was common. For the MSP-119 triple
variant, 21/32 samples tested positive for specific IgG3, and
titers were higher in patients with parasitological cure (median
ODs, 0.533 versus 0.107; P 0.048). Similar results were found
with responses to the wild-type antigen.
The triple-variant protein used in these studies lacks block-
ing epitopes present in the wild-type protein, and the antibody
responses found in the present study were consistent with this.
Mean day 7 anti-MSP-119 IgG levels were higher to the WT
than to the triple-variant protein (Table 3), and at an individ-
ual level, IgG binding to the triple variant was always similar to
or lower than that binding to WT antigen (Fig. 1). Several
individuals who cleared their infections show concordant re-
sponses (Fig. 1); however, the figure also shows that children
are more likely to clear their infections if they have antibody
levels above the median. Thus, although this method may be
suitable to examine the importance of differential fine speci-
ficity in naturally occurring antibodies, larger group sizes will
be necessary.
DISCUSSION
In this retrospective study, we have investigated whether
antibodies to two key P. falciparum merozoite surface mole-
cules, AMA-1 and MSP-119, are associated with clinical recov-
ery and control of parasitemia in children undergoing treat-
ment for uncomplicated malaria in an area of high prevalence
of drug resistance. Anti-MSP-119 antibodies were associated
with clinical recovery and control of parasitemia, while the
presence of antibodies to AMA-1 was only weakly associated
with clinical recovery and was not associated with control of
parasitemia. If these associations are causal, the results suggest
TABLE 3. Parasitological outcome and day 7 IgG titers to AMA-1 and MSP-119 variants
a
Antigen No. ingroup
Median outcome value (25th, 75th percentiles) in cases of parasitological outcome
OD IgG concn (ng/ml)
Failure Clearance P value Failure Clearance P value
AMA-1 27 3.215 (2.016, 3.843 [0.58]) 3.048 (1.505, 3.341) 0.58 ND ND
WT MSP-119 30 1.980 (1.567, 3.019 [0.083]) 2.848 (2.484, 3.941) 0.083 37.03 (21.89, 67.33 [0.057]) 103.68 (52.22, 402.94) 0.057
Triple-variant
MSP-119
29 1.627 (1.257, 2.730 [0.097]) 2.536 (2.140, 3.745) 0.097 17.63 (12.00, 49.35 [0.057]) 66.83 (29.95, 300.96) 0.057
Double-variant
MSP-119
29 1.497 (1.086, 2.325 [0.223]) 2.416 (1.513, 3.681) 0.223 ND ND
a Specific IgG was detected by ELISA in plasma collected on day 7 from children infected with the Pfcrt-76Thr genotype parasite, and results of positive responders
are presented according to parasitological failure or clearance. For AMA-1, seven of the 27 positive responders cleared their parasites, and for the MSP-119 antigens
eight of the 30 or 29 positive responders cleared theirs. Samples were tested at a 1:1,000 dilution for all antigens, and median OD values are presented. IgG
concentrations for WT and triple-variant MSP-119 antigens were then obtained by titration (see Materials and Methods). P values were estimated using the two-sample
Wilcoxon rank-sum test. ND, not done.
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that therapeutic responses to malaria treatment can be useful
measures of effective clinical immunity.
As this was a retrospective study, selection of samples for anal-
ysis was constrained by their availability. This could have caused
bias, but we found no difference in age, clinical outcome, or
ethnicity between children who provided sera and those who did
not. Two of the most likely confounders of the association of
antibody and therapeutic response, age and drug-resistant geno-
type (10), were examined in detail. Age was not associated with
anti-MSP119 concentrations in the present study, but the associ-
ation between treatment outcome and antibody levels on day 0
appeared to be stronger in children infected with parasites carry-
ing the Pfcrt-76Thr allele. The influence of this confounder was
avoided when studying the day 7 responses by restricting the
analysis to those carrying the Pfcrt-76Thr allele. Genetic varia-
tions associated with the sickle cell trait (HbS) or ethnicity also
influence the occurrence of malaria in African populations,
and both appear to be associated with higher antibody re-
sponse levels to malaria antigens (3, 5). In the present study, no
pattern linking therapeutic response or antibody levels and
ethnicity was discernible (results not shown), but this, along
with the influence of HbS, needs to be studied in a larger
group.
Whereas our findings are not incompatible with those of
previous studies that have identified AMA-1 and MSP-119 as
candidate target antigens for vaccines, we have no specific
evidence that antibodies recognizing these proteins are protec-
tive. We have shown that children who clinically recover after
treatment are more likely to carry antibody recognizing these
antigens. Extensive data from studies conducted in vitro, in
animal models, and some malaria-exposed populations sup-
port AMA-1 as a vaccine candidate (e.g., reference 32); we
found that IgG recognizing MSP-119 is more robustly associ-
ated with functional immunity than is that recognizing AMA-1.
Direct comparisons between these antigens, however, should
be made with caution, as they were not expressed in the same
vector and the dynamics of the humoral response may vary
between antigens. Our findings with MSP-119 agree with other
studies linking anti-MSP-119 antibodies and protection from
clinical malaria (e.g., references 1 and 15) and with a longitu-
dinal study of Kenyan infants showing a clear relationship
between the presence of anti-MSP-119 antibodies and afebrile,
as opposed to febrile, infection (4). However, epidemiological
evidence of an association of anti-MSP-119 responses with pro-
tection from clinical malaria has been conflicting, possibly re-
flecting the different methodologies that have been employed.
The only previous study of anti-MSP-1 antibodies and thera-
peutic responses (23) found an association between therapeu-
tic success and prevalence of antibody to MSP-1 block 2 anti-
gens but not to MSP-119. This might reflect the lower prevalence
of drug resistance in that study (33% compared to 79% for our
patients), and stronger associations may be expected among
patients infected with drug-resistant parasites. Also, some co-
hort studies (e.g., reference 12) found no correlation between
anti-MSP-119 antibodies and malaria attacks, but our results
show that anti-MSP-119 antibody measured during the low-
FIG. 1. Comparison of IgG concentrations to wild-type MSP-119 and to the triple variant in individual day 7 plasma samples. Variation between
the IgG concentration (ng/ml) in day 7 plasma specific for WT and that for triple-variant MSP-119 is shown. Data from 37 subjects were ranked
along the x axis according to their responses to the triple variant. E and ‚, WT MSP-119, with ‚ indicating cases with parasitological failure; ✳,
triple variant.
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transmission season may not be a good predictor of levels or
prevalence during clinical attacks in the high-transmission sea-
son. The dynamics of these responses may explain the variable
association between anti-MSP-119 antibodies and protection
from clinical attacks found in different studies and are worthy
of further investigation.
Our results are, as far as we are aware, the first to show an
association of parasite density with anti-MSP-119 IgG concen-
tration during a malaria episode. The presence of a biological
gradient increases the likelihood of causality and underlines an
advantage in the use of therapeutic responses as an assay of
functional immunity. It also supports the possibility that anti-
MSP-119 IgG is a component of protection in these children.
However, the associations we have observed also simply could
reflect the higher level of exposure experienced by those chil-
dren who are semi-immune, and the truly protective compo-
nents of acquired immunity may be elicited by other antigens
or factors we have not examined.
Cohort studies and therapeutic responses to drug treatment
studies may measure different aspects of immunity. In cohort
studies, functional immunity can be defined as a lower proba-
bility of developing clinical malaria, a higher parasitemia level,
or infection (15, 32) and thus includes preerythrocytic immune
responses against sporozoite and liver stages. The therapeutic
approach, on the other hand, can define functional immunity
as the ability to recover clinically or to control parasitemia,
both of which may differ in mechanism from the ability to
maintain parasitemia below clinically significant levels or to
prevent infection. The therapeutic approach may thus identify
protective mechanisms of greater relevance to reducing the
clinical burden of disease. For example, in the current study,
the presence of anti-MSP-119 IgG antibodies at consultation
was associated with clinical recovery; if the relationship is
causal, such antibodies may play a role in reducing child mor-
bidity.
The IgG subclass analysis confirmed results from previous
population studies with the IgG1 antibody subclass predomi-
nating for both AMA-1 and MSP-119 and with an additional
IgG3 response to MSP-119 (7, 32). The relative balance of
antibody binding to the wild-type and triple-variant MSP-119
supports the hypothesis that one or more epitopes on the
wild-type antigen are recognized by some malaria-exposed in-
dividuals but not by others (30). Future studies could examine
the association between differences in antibody fine specificity
and clinical outcome. The similarities in IgG responses in pa-
tients with malaria and in clinically well, malaria-exposed pop-
ulations, together with the associations between therapeutic
and IgG responses, are consistent with results obtained by use
of several other approaches. These similarities indicate that
the current methods could be usefully applied to analyze other
antigens.
Antimalarial drug treatment policy in sub-Saharan Africa
requires accurate data on the degree and distribution of drug
resistance in the parasite population, data that are typically
generated from in vivo therapeutic efficacy studies. Collabora-
tion on future therapeutic efficacy studies to allow collection of
plasma from well-characterized patients may thus be possible,
and this approach has been suggested as an ethical alternative
to population-based studies (11). A recent review suggests that
the number of available antigens is not a rate-limiting step for
vaccine development (29) and that a better definition of the
antigens we already have, for example an analysis using the
modified MSP-119 antigens as shown here, might be an efficient
approach to define the antigenic components of effective ma-
laria vaccines.
In conclusion, our results demonstrate that the presence of
IgG to AMA-1 and MSP-119 on the day of consultation may
protect against clinical failure, and that higher titers of IgG to
MSP-119 enhance the likelihood of parasitological clearance in
individuals treated with a suboptimal drug regime; they there-
fore support the use of therapeutic response studies to char-
acterize candidate vaccine antigens.
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